

## AUDITORS' REPORT

on

### Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of Silva Pharmaceuticals Limited for the month ended 31 August 2021 as per required by Bangladesh Securities and Exchange and Commission (BSEC) under Section 2CC of the Securities and Exchange Ordinance 1969.

#### Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June 2018 and other applicable laws and regulations.

#### Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 2, 3, 5 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations, gives a true and fair view of the statement for the month 31 August 2021.

#### As per TOR, we draw attention to the following matter:

1. During the month of August, 2021 no expenses has been incurred in respect of Civil Construction. However, the company has utilized accumulative amount of Tk. 60,532,650 up to 31 August 2021 which was 104.26% of the amount specified in the prospectus and thereafter revised utilization plan for the purpose of Civil Construction. As such, approval was a pre-requisite from the respected shareholders and concerned regulatory authority for the excess utilized amount of Tk. 2,474,124.




2. During the month of August, 2021 no expenses has been incurred in respect of Purchase new Machinery and Equipment's. However, the company has utilized accumulative amount of Tk. 32,585,847 which was 26.60% up to 31 August 2021 in respect of Purchase of Machinery and Equipment's.
3. The Company has utilized Tk. 99,000,000 which was 100% of the budgeted amount up to 31 August 2021 for the purpose of loan repayment as specified in the prospectus.
4. The Company has utilized Tk. 20,441,474 which was 100% of the budgeted amount up to 31 August for the purpose of IPO expenses as specified in the prospectus and thereafter revised utilization plan.

**We also state that:**

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus and thereafter revised utilization plan except the above said issues no.1 of the Company;
- b) IPO proceeds have been utilized in so far line with the conditions of the BSEC's consent letter for the IPO except the above said issues no. 1.
- c) The time frame for completion of the utilization of IPO proceeds was revised and will be completed within the time frame as specified in the resolution of 19<sup>th</sup> Annual General Meeting (AGM).
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus and 18<sup>th</sup> AGM of the Company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

**Dhaka**  
Dated: 09 September 2021



**Mohan Adhikari, FCA**  
**Partner**

ICAB Enroll no: 1729

**Pinaki & Company**  
Chartered Accountants




**Report on Utilization of IPO Proceeds**  
For the Month of August 2021


Name of the Company: **Silva Pharmaceuticals Limited**  
Amount (BDT) of capital raised through IPO: **BDT 300,000,000**  
Date of Close of Subscription: **05 August 2018**  
Proceeds Receiving Date: **10 October 2018**  
Last Date of Full Utilization of IPO Fund as per Prospectus: **As stated in time line columns**


| S.L.         | Purpose mentioned in the prospectus / 18th AGM | Time Line         |                 | Amount as per Prospectus | Amount as per 18th AGM | Amount as per Prospectus per 18th AGM | Status of Utilization |          |                  |                       | Remarks     |                   |                        |
|--------------|--|-------------------|-----------------|--------------------------|------------------------|---------------------------------------|-----------------------|----------|------------------|-----------------------|-------------|-------------------|------------------------|
|              |  | As per Prospectus | As per 18th AGM |                          |                        |                                       | As per 19th AGM       | Opening  | During the Month | Total Utilized Amount |             | Utilized %        | Excess Utilized amount |
| 1            | Civil Construction                             | 09.04.2020        | 09.10.2020      | 31.12.2022               | 58,058,526             | 56,000,000                            | 60,532,650            | -        | 104.26           | 2,474,124             | 4.26        | -                 | -                      |
| 2            | Machinery and Equipment                        | 09.04.2020        | 09.10.2020      | 31.12.2022               | 122,500,000            | 122,500,000                           | 32,585,847            | -        | 26.60            | -                     | -           | 89,914,153        | 73.40                  |
| 3            | Repayment of Bank Borrowing at prospectus      | 09.01.2019        | N/A             | N/A                      | 99,000,000             | 99,000,000                            | 99,000,000            | -        | 100.00           | -                     | -           | -                 | -                      |
| 4            | IPO Expenses                                   | N/A               | N/A             | N/A                      | 20,441,474             | 20,441,474                            | 20,441,474            | -        | 100.00           | -                     | -           | -                 | -                      |
| <b>Total</b> |  |                   |                 |                          | <b>300,000,000</b>     | <b>300,000,000</b>                    | <b>212,559,971</b>    | <b>-</b> | <b>70.85</b>     | <b>2,474,124</b>      | <b>0.82</b> | <b>89,914,153</b> | <b>29.97</b>           |


**Notes:**


- Actual application was received almost 25.76 Times.
- IPO proceeds have been utilized for the purposes/heads as specified in the prospectus and in line with the condition of the Commission's consent letter.
- Interest on IPO Proceeds in BDT (from FDR & SND) -  
22,704,810  
110,144,840
- Un-Utilized IPO Proceeds with interest income in BDT -

  
**Silvana Mirza**  
Chairman

  
**Dr. Saira Khan**  
Managing Director

  
**Md. Abul Kasem**  
Chief Financial Officer

  
**Md. Anwar Hossain**  
Company Secretary

  
**Mohan Adhikari, FCA**  
Partner  
ICAB Enroll. No. 1729  
**Pinaki & Company**  
Chartered Accountants

Dhaka  
Dated : 09 September 2021